These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31030650)

  • 1. Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping.
    Thomas SE; Collins P; James RH; Mendes V; Charoensutthivarakul S; Radoux C; Abell C; Coyne AG; Floto RA; von Delft F; Blundell TL
    Philos Trans A Math Phys Eng Sci; 2019 Jun; 377(2147):20180422. PubMed ID: 31030650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Inhibitors of SAICAR Synthetase (PurC) from
    Charoensutthivarakul S; Thomas SE; Curran A; Brown KP; Belardinelli JM; Whitehouse AJ; Acebrón-García-de-Eulate M; Sangan J; Gramani SG; Jackson M; Mendes V; Floto RA; Blundell TL; Coyne AG; Abell C
    ACS Infect Dis; 2022 Feb; 8(2):296-309. PubMed ID: 35037462
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
    Silvestre HL; Blundell TL; Abell C; Ciulli A
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based approaches in drug discovery and chemical biology.
    Scott DE; Coyne AG; Hudson SA; Abell C
    Biochemistry; 2012 Jun; 51(25):4990-5003. PubMed ID: 22697260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fast fragment and compound screening pipeline at the Swiss Light Source.
    Stegmann DP; Steuber J; Fritz G; Wojdyla JA; Sharpe ME
    Methods Enzymol; 2023; 690():235-284. PubMed ID: 37858531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification.
    Thomas SE; Whitehouse AJ; Brown K; Burbaud S; Belardinelli JM; Sangen J; Lahiri R; Libardo MDJ; Gupta P; Malhotra S; Boshoff HIM; Jackson M; Abell C; Coyne AG; Blundell TL; Floto RA; Mendes V
    Nucleic Acids Res; 2020 Aug; 48(14):8099-8112. PubMed ID: 32602532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
    Rudling A; Gustafsson R; Almlöf I; Homan E; Scobie M; Warpman Berglund U; Helleday T; Stenmark P; Carlsson J
    J Med Chem; 2017 Oct; 60(19):8160-8169. PubMed ID: 28929756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchrotron radiation biomedical imaging and radiotherapy: from the UK to the Antipodes.
    Hall C; Lewis R
    Philos Trans A Math Phys Eng Sci; 2019 Jun; 377(2147):20180240. PubMed ID: 31030651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast fragment- and compound-screening pipeline at the Swiss Light Source.
    Kaminski JW; Vera L; Stegmann DP; Vering J; Eris D; Smith KML; Huang CY; Meier N; Steuber J; Wang M; Fritz G; Wojdyla JA; Sharpe ME
    Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):328-336. PubMed ID: 35234147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based approach to drug lead discovery: overview and advances in various techniques.
    Fattori D; Squarcia A; Bartoli S
    Drugs R D; 2008; 9(4):217-27. PubMed ID: 18588353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors.
    Martinez-Rosell G; Harvey MJ; De Fabritiis G
    J Chem Inf Model; 2018 Mar; 58(3):683-691. PubMed ID: 29481075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery.
    Yamaotsu N; Hirono S
    J Comput Aided Mol Des; 2018 Nov; 32(11):1229-1245. PubMed ID: 30196523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying Interactions that Determine Fragment Binding at Protein Hotspots.
    Radoux CJ; Olsson TS; Pitt WR; Groom CR; Blundell TL
    J Med Chem; 2016 May; 59(9):4314-25. PubMed ID: 27043011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures.
    Erlanson DA; Davis BJ; Jahnke W
    Cell Chem Biol; 2019 Jan; 26(1):9-15. PubMed ID: 30482678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interview with Jonathan Baell, PhD.
    Napper AD
    Assay Drug Dev Technol; 2016 Apr; 14(3):164-7. PubMed ID: 27078678
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.